Bristol/Otsuka’s Abilify New Rx Share Exceeds 10%
This article was originally published in The Pink Sheet Daily
Total scripts for the atypical antipsychotic were 700,000 in the fourth quarter, up more than 10% sequentially. Abilify has received additional sales support from Bristol despite the company’s reduction in the overall size of its detail team.
You may also be interested in...
The atypical antipsychotic's new formulation will be available in February, the companies say. Abilify is the second drug in the class available as an oral solution, after J&J's Risperdal. Supplemental NDAs for additional Abilify formulations are pending at FDA, Bristol says.
FDA clears aripiprazole for the treatment of acute manic and mixed episodes associated with bipolar disorder. The approval places Abilify labeling on par with other atypical antipsychotics.
ClinROs, artificial intelligence-based algorithms will be included in approval pathway. FDA is taking a crash course on new techniques for trial assessment thanks to COVID.